- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Bimzelx® | CA028_0496 | CDP4940 | gL7gH9 | UCB-4940 | UCB4940 | Zu-G1
bimekizumab is an approved drug (EMA (2021))
Compound class: Antibody
Comment: Bimekizumab (UCB4940) is a rat-derived humanized Phase 2 monoclonal antibody targeting both IL-17A and IL-7F (dual antagonist), with potential for controlling autoimmune conditions mediated by these proinflammatory cytokines. Safety, pharmacokinetics and clinical efficacy of bimekizumab in mild psoriasis are reported in . Claimed in patent WO2008047134 as CA028_0496 .
|Bimekizumab is a rat-derived humanized anti-IL-17A/L-7F mAb that has potential for controlling autoimmune conditions mediated by these proinflammatory cytokines.|